



Subject: Selective Internal Radiation Therapy (SIRT)*

Effective Date: April 28, 2009

Department(s): Utilization Management

Policy: Selective Internal Radiation Therapy (SIRT) with ⁹⁰yttrium-containing resin spheres is reimbursable under Plans administered by QualCare, Inc.

Objective: To assure proper and consistent reimbursement and to delineate circumstances under which a specific therapeutic intervention is to be authorized.

Procedure:

1. Diagnoses for which SIRT is reimbursable are following liver malignancies when unresectable or medically inoperable and life expectancy is at least three months, with Eastern Cooperative Oncology Group(ECOG) performance status no greater than 2 or Karnofsky Performance Scale(KPS) of 70 or more:
 1. Primary hepatocellular carcinoma (**ICD-9 155.0, ICD-10 C22.0**)
 2. Metastatic hepatic lesions arising from colorectal cancer (**ICD-9 197.7, ICD-10-C78.7**)
 3. Metastatic hepatic only or hepatic predominant lesions arising from neuroendocrine tumors(carcinoid, islet cell, pancreatic endocrine -**ICD-9 197.7, ICD-10 C78.7**)
 4. Unresectable intrahepatic cholangiocarcinoma (**ICD 9-155.1, ICD-10 C22.1**)
2. SIRT is not reimbursable for any other indication
3. Repeat SIRT is reimbursable for new or progressive, primary or metastatic liver cancers as outlined in A above when all of the following are present:

- a. A previous satisfactory response to SIRT as indicated by CT or PET-CT imaging performed 3 months after the previous procedure.
- b. The disease is still liver predominant.
- c. Life expectancy of at least three months.
- d. ECOG performance status no greater than 2 or KPS of 70 or more
- e. There are no other effective systemic or liver-directed treatment options.
- f. Treatment will be to a targeted tumor volume(e.g. not whole liver).

Note-repeat whole liver SIRT is not reimbursable as it is considered experimental, investigational, or unproven.

Note- SIRT is provided only in the outpatient setting unless the documentation supports the medical necessity of inpatient treatment.

4. **CPT** codes applicable to SIRT are:
 1. **C2616** (for the ⁹⁰yttrium-containing resin spheres)
 2. **S2095** (for the deployment of the spheres)

References

Townsend AR, Chong LC, Karapetis C, Price TJ. Selective internal radiation therapy for liver metastases from colorectal cancer. *Cancer Treat Rev.* 2016;50:148-154(Nov)

Khajornjiraphan N, Thu NA, Chow PK. Yttrium-90 microspheres: a review of its emerging clinical indications. *Liver Cancer.* 2015;4(1):6-15(Mar)

National Comprehensive Cancer network (NCCN) Guidelines Version 2.2015- Hepatobiliary Cancer. Accessed at NCCN.org

Kuei A, Saab S, Cho SK, KEE ST, Lee SW. Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. *World J Gastroenterol.* 2015;21(27):8271-83(Jul)

Kennedy AS, Ball D, Cohen SJ, Cohn M, et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. *J Gastrointest Oncol.* 2015;6(2):134-42(Apr)

ACR-SIR practice parameter for radioembolization with microsphere brachytherapy device (RMBD) for treatment of liver malignancies. Revised 2014. Accessed at <http://www.acr.org/~media/ACR/Documents/PGTS/guidelines/RMBD.pdf>

Hayes Health technology Brief- Transarterial Hepatic Yttrium-90 Radioembolization for Treatment of Unresectable Intrahepatic Cholangiocarcinoma. Updated December 22, 2014. Accessed at Hayesinc.com

Lam MG, Louie JD, Iagaru AH, Goris ML, Sze DY. Safety of repeated yttrium-90 radioembolization. *Cardiovasc Intervent Radiol*. 2013 Oct;36(5):1320-8

Mouli S, Memon K, Baker T, Benson AB, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. *J Vasc Interv Radiol* 2013; 24: 1227-1234(Aug)

Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. *Cancer Control*. 2011;18(2): 127-137.(Apr)

Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres- safety, efficacy, and survival. *Radiology*.2008;247(2):507-15(May)

Rhee TK, Lewandowski RJ, Liu DM, Mulcahy MF, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. *Ann Surg*. 2008; 247(6):1029-35 (Jun)

Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. *Am J Clin Oncol*. 2008;31(3):271-279.

Curley SA, Stuart KE, Schwartz JM, et al. Nonsurgical therapies for localized hepatocellular carcinoma. *UpToDate* v 16.3 2008 (Oct 1) Available at www.uptodate.com/online/content/topic.do?topicKey=gicancer/16195&view=print. Accessed 03/20/09

Venook AP. Nonsurgical treatment strategies for colorectal cancer liver metastases. *UpToDate* v 16.3 2008 (Oct 1). Available at www.uptodate.com/online/content/topic.do?topicKey=gicancer/5245&view=print. Accessed 03/20/09

Dubel GJ, Soares GM. Regional infusion-radioembolization. *Surg Oncol* 2008;17(4):957-985 (Oct)

Kemeny N, Kemeny M, Dawson L. Liver Metastases. Ch 59 in Abeloff MD, Armitage JO, Niderhuber JE, et al. *Abeloff's Clinical Oncology* 4th ed. Philadelphia. Churchill Livingstone Elsevier. 2008

Rowe BP, Weiner R, Foster J, et al. ⁹⁰Yttrium microspheres for nonresectable liver cancer: the University of Connecticut Health Center experience. *Conn Med* 2007;71(9):523-528 (Oct)

Khodjibekova M, Szyszko T, Khan S, et al. Selective internal radiation therapy with Yttrium-90 for unresectable liver tumours. *Rev Recent Clin Trials* 2007;2(3):212-216 (Sep)

Garrean S, Hering J, Helton S, et al. A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumors. *Am J Surg* 2007;194(1):79-88 (Jul)

Garrean S, Muhs A, Bui JT, *et al.* Complete eradication of hepatic metastasis form colorectal cancer by Yttrium-90 SIRT. *World J Gastroenterol* 2007;13(21):3016-3019 (Jun 7)

Szyszkowski T, Al-Nahhas A, Canelo R, *et al.* Assessment of response to treatment of unresectable liver tumours with ⁹⁰Y microspheres: Value of FDG PET versus computed tomography. *Nucl Med Commun* 2007;28(1):15-20 (Jan)

Stubbs RS, O'Brien I, Correia, MM. Selective internal radiation therapy with ⁹⁰Y microspheres for colorectal liver metastases: Single-centre experience with 100 patients. *ANZ J Surg* 2006;76(8):696-703 (Aug)

Welsh JS, Kennedy AS, Thomadsen B. Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. *Int J Radiat Oncol Biol Phys* 2006;66(2Suppl):S62-S73 (Jan)

Drafted By/Date: BFisher, MD 03/20/09

Approved By/Date: QM Committee 04/28/09

Revised By/Date: MMcNeil, MD

Approved By/Date: QM Committee, 07/26/11

Revised By/Date: MMcNeil, MD 08/28/15

Approved By/Date: QM Committee 9/29/15

Revised By/Date: MMcNeil, MD 06/01/17

Approved By/Date: QM Committee 6/20/17

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.